Access to essential medicines for sexual and reproductive health care: The role of the pharmaceutical industry and international regulation

Reproductive Health Matters

Volumn 19, Issue 38, 2011, Pages 69-84

  Cottingham, Jane ^a   Berer, Marge ^a  

^a NONE

Author keywords

Essential medicines; Female condoms; Hormone replacement therapy; Human papillomavirus and vaccination; Medical abortion pills; Microbicides; Pharmaceutical industry; Reproductive and sexual health care

Indexed keywords

ANTIRETROVIRUS AGENT; ESTROGEN; GENERIC DRUG; MAGNESIUM SULFATE; MICROBICIDE; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN; TESTOSTERONE; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER PREVENTION; CHLAMYDIASIS; CONDOM; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; GONORRHEA; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INDUCED ABORTION; INTERNATIONAL COOPERATION; INTERNET; MASS SCREENING; PAPILLOMAVIRUS INFECTION; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC-PRIVATE PARTNERSHIP; REPRODUCTIVE HEALTH; SEXUALLY TRANSMITTED DISEASE; STANDARD; SYPHILIS; TRICHOMONIASIS; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

DRUG INDUSTRY; DRUGS, ESSENTIAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONALITY; MALE; REPRODUCTIVE HEALTH SERVICES;

EID: 82355194753     PISSN: 09688080     EISSN: 14609576     Source Type: Journal    
DOI: 10.1016/S0968-8080(11)38573-4     Document Type: Article

References (65)

1. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets 2004, World Health Organization, WHO, Geneva.
2. Affordable drugs for so-called diseases of poverty. PROCAARE Healthnet. 13 September 2007.
3. Goal 8: a global partnership for development. New York, UNDP UN Development Programme, At: Accessed 10 August, 2011. http://www.undp.org/mdg/goal8.shtml.
4. Millennium Development Goal 8: the global partnership for development at a critical juncture 2010, United Nations MDG Gap Task Force, UN MDG Gap Task Force Report, New York.
5. World Contraceptive Use 2009 2009, United Nations, UN, New York.
6. Research Report on China's Condom Market, 2009 China Research Intelligence, At: Accessed 9 August 2011. http://www.prlog.org/10180042-research-report-on-chinas-condom-market-2009.html.
7. Singh S, Darroch JE, Ashford LS, et al. Adding It Up: The costs and benefits of investing in family planning and maternal and newborn health 2009, Guttmacher Institute, UN Population Fund, New York.
8. Essential Medicines for Reproductive Health: Guiding principles for their inclusion on national medicines lists 2006, PATH, World Health OrganizationWorld Health Organization, United Nations Population FundUnited Nations Population Fund, PATH, Seattle, At: Accessed 9 August 2011. http://www.who.int/reproductivehealth/publications/general/a91388/en/index.html.
9. Furedi A New emergency contraceptive method ellaOne® - is it worth the price?. Reproductive Health Matters 2009, 17(34):187-188.
10. Sinding S, Bongaarts J Response to letter from Petroni S. International Perspectives on Sexual and Reproductive Health 2009, 35(3). At: http://www.guttmacher.org/pubs/journals/3515309.html.
11. Drake JK, Thi Thanh LH, Suraratdecha C, et al. Stakeholder perceptions of a total market approach to family planning in Viet Nam. Reproductive Health Matters 2010, 18(36):46-55.
12. Ravindran TKS Privatisation in reproductive health services in Pakistan: three case studies. Reproductive Health Matters 2010, 18(36):13-24.
13. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008 2011, World Health Organization, WHO, Geneva.
14. Trends in maternal mortality: 1990 to 2008 2010, WHO, UNICEFUNICEF, UNFPAUNFPA, World BankWorld Bank, World Health Organization, Geneva.
15. Shah I, Ahman E Unsafe abortion in 2008: global and regional levels and trends. Reproductive Health Matters 2010, 18(36):90-101.
16. Global burden of disease. Geneva, 2004. Update World Health Organization, At: Accessed 9 August 2011. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
17. The Interagency List of Essential Medicines for Reproductive Health 2006, World Health Organization, WHO, Geneva.
18. Service availability mapping World Health Organization, At: Accessed 9 August, 2011. http://www.who.int/healthinfo/systems/samintro/en/index.html.
19. Prevalence and incidence of selected sexually transmitted infections: Chlamydia, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis 2011, World Health Organization, WHO, Geneva.
20. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015 2006, World Health Organization, WHO, Geneva.
21. UNAIDS report on the global AIDS epidemic 2010 2010, 16. Joint United Nations Programme on HIV/AIDS, UNAIDS, Geneva.
22. Mother-to-child transmission of HIV World Health Organization, At: Accessed 9 August 2011. http://www.who.int/hiv/topics/mtct/en/index.html.
23. Guidelines on HIV and infant feeding 2010 2010, World Health Organization, WHO, Geneva.
24. United Nations. International Covenant on Economic, Social and Cultural Rights. UN General Assembly, 1966; and General Comment No.14: the right to the highest attainable standard of health. New York: United Nations, Committee on Economic, Social and Cultural Rights, 2000.
25. Essential medicines programme World Health Organization, At: Accessed 9 August 2011. http://www.who.int/medicines/areas/policy/en/index.html.
26. Commercial Insight: hormonal contraceptives - look beyond oral contraception for a competitive edge. October 2009 Datamonitor, At: Accessed 9 August, 2011. http://www.researchandmarkets.com/research/f10fda/commercial_insight.
27. Shahani S. Cardiovascular medicine: diagnostics, drugs and devices. BCC Research. Report ID:HLC041B. November 2007.
28. See, for example, "Age critique - âge dynamique", a brochure published by Wyeth for women and distributed throughout Switzerland in pharmacies (Undated). It specifically states that "HRT does not increase risk of breast cancer; it might even diminish it." (p.39).
29. Krieger N, Löwy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical and advocacy perspectives. Journal of Epidemiology and Community Health 2005, 59:740-748.
30. Farquhar CM, Marjoribanks J, Lethaby A, et al, and the Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women (Review). 2007.
31. Shahani S Hormone replacement therapies and other hormone therapies: global markets. BCC ResearchReport ID:PHM055A. September 2008 At: Accessed 9 August 2011. http://www.bccresearch.com/report/PHM055A.html.
32. Global Burden of Disease, 2004 update 2008, World Health Organization, WHO, Geneva.
33. Ferlay J, Bray F, Pisani P, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide 2004, IARC Press, Lyon, Cited in: Tsu VD, Levin CE. Making the case for cervical cancer prevention: what about equity? Reproductive Health Matters 2008;16(32):104-12.
34. Summary Chapter. Screening for Cancer of the Uterine Cervix 1986, 133-142. International Agency for Research on Cancer Working Group on Cervical Cancer Screening, IARC, Lyon. M. Hakama, A.B. Miller, N.E. Day (Eds.).
35. Banura C, Mirembe FM, Katahoire AR, et al. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: a systematic review. Infectious Agents and Cancer 2011, 6(1):11.
36. Harris T, Burke RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005, 293:1471-1476.
37. Chesson HW, Ekwueme DU, Saraiva M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccines 2011; August 1, E-pub. (abstract only).
38. Dietz CA, Nyberg CR Genital, oral and anal human papillomavirus infection in men who have sex with men. Journal of American Osteopathic Association 2011, 111(3 Suppl.2):S19-S25. (abstract only).
39. Margolis S HPV Vaccine controversy continues. Yahoo Health, 21 March 2007 At: Accessed 9 August 2011. http://health.yahoo.net/search?q1=vaccine+controversy.
40. Rothman SM, Rothman DJ Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009, 302(7):781-786. doi:10.1001/jama.2009.1179.
41. Outterson K Will HPV vaccines prevent cervical cancers among poor women of color?: global health policy at the intersection of human rights and intellectual property law. American Journal of Law & Medicine 2009, 35:247-252.
42. Roose-Snyder B, Doyle MK The global health licensing program: a new model for humanitarian licensing at the university level. American Journal of Law and Medicine 2009, 35(2/3):281-309.
43. Bird R Developing country nations and compulsory licensing: maximizing access to essential medicines while minimising investment side effects. Journal of Law, Medicine & Ethics 2009, Summer:209-221.
44. Bhardwaj K. Access to medicines and treatment - a reality check. Reported in: Repoliticizing sexual and reproductive health and rights: report of a global meeting, Langkawi, Malaysia, 3-6 August 2010. London: Reproductive Health Matters and Asian-Pacific Resource and Research Centre for Women, 2011.
45. Yu P Access to medicines, BRICS alliance and collective action. American Journal of Law and Medicine 2008, 34:345-394.
46. Drug company reacts to Thai license: government ready to talk. 16 February 2007 Intellectual Property Watch, At: Accessed 9 August 2011. http://www.ip-watch.org/weblog/2007/02/16/drug-company-upset-by-newest-thai-license-government-open-to-dialogue.
47. Love JP Recent examples of the use of compulsory licenses on patents 2007, Knowledge Ecology International, London, At: Accessed 9 August 2011. http://keionline.org/content/view/41/1.
48. Mudur G India's proposed pact with Europe may choke its generic drug exports, health rights activists fear. BMJ 2011, 342:d1480.
49. Zaracostas J Trade talks on patent protection violate right to health, allege advocacy groups. BMJ 2011, 342:d1993.
50. Report to the General Assembly of the United Nations Special Rapporteur on the right to the highest attainable standard of health. A/63/263 2008, UN, New York.
51. Beer K, Armand F Assessment of India's locally manufactured contraceptive product supply 2006, Private Sector Partnerships-One Project, Abt Associates Inc, Bethesda, MD.
52. Rwanda, Merck and QIAGEN launch Africa's first comprehensive cervical cancer prevention program incorporating both HPV vaccination and HPV testing Merck & Co, Inc, At: Accessed 15 August 2011. http://www.merck.com/newsroom/news-release-archive/vaccine-news/2011_0425.html.
53. Annual report 2006, Ingelheim. Boehringer Ingelheim GmbH, 2007.
54. Merck & Co, Inc. Looking ahead: 2009-2010 corporate responsibility review. Whitehouse Station, NJ, 2010.
55. HIV/AIDS: Gilead first to join Medicines Patent Pool. IRIN PlusNews. Nairobi, 12 July 2011.
56. Medicines: counterfeit medicines. Fact Sheet No.275, January 2010 World Health Organization, At: Accessed 9 August 2011. http://www.who.int/mediacentre/factsheets/fs275/en/index.html.
57. Park CS Legal aspects of defining "counterfeit medicines". A discussion paper 2009, World Health Organization, New Delhi.
58. Mulumba M Anti-counterfeiting legislation in East Africa: a new assault against TRIPS flexibilities for access to medicine? 2010, Centre for Health, Human Rights and Development, Kampala.
59. Boseley S. Scandal of Africa's missing medicines. Guardian Weekly. 2 October 2009. p.42-43.
60. Proof of concept established for microbicides International Partnership for Microbicides, At: Accessed 9 August 2011. http://www.ipmglobal.org/publications-media/proof-concept-established-microbicides.
61. Peters A, Jansen W, van Driel F The female condom: the international denial of a strong potential. Reproductive Health Matters 2010, 18(35):119-128.
62. New partnership supports reproductive health options for women. 2001 PATH, At: Accessed 9 August 2011. http://www.path.org/news/an110214-womans-condom.php.
63. Banerjee A, Hollis A, Pogge T The Health Impact Fund: incentives for improving access to medicines. Lancet 2010, 375:166-169.
64. Htay TT Making pregnancy safer in Myanmar: introducing misoprostol to prevent post-partum haemorrhage as part of active management of the third stage of labour. Reproductive Health Matters 2007, 15(30):214-215.
65. 't Hoen E, Berger J, Calmy A, et al. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. Journal of International AIDS Society 2011, 14:15.